Researchers are studying a few new and existing drugs to treat FSGS. FSGS needs a novel medication that regulates both high body fats and inflammasome inhibition via upstream innate immune system to block intracellular initiation of inflammatory cascade and extra cellular inflammation. Over the past five years, nearly 30% of Biorasi-initiated or ongoing studies involved chronic kidney disease. Our experience allows us to develop successful nephrology clinical trials.
“What we need to do is to keep working on getting biomarkers more defined to be able to differentiate between the different etiologies. This is going to be [...]
Managing the Complexities of Clinical Trials in the Dialysis-Dependent CKD Population Chronic kidney disease is a serious, slowly progressing condition, culminating in end-stage renal disease. Developers of [...]